SURGIFOAM ABSORBABLE GELATIN SPONGE, USP
Ferrosan Meidcal Devices A/S · Decision date Sep 30, 1999
What did the FDA approve?
FDA approved PMA P990004 for SURGIFOAM Absorbable Gelatin Sponge, U.S.P. on September 30, 1999. The approval statement describes the device as indicated for hemostasis in surgical procedures, excluding urologic, ophthalmic, and neurologic procedures, when control of capillary, venous, and arteriolar bleeding by pressure, ligature, and other conventional procedures is ineffective or impractical.
The applicant is Ferrosan Medical Devices A/S, and the device is categorized as an absorbable hemostatic agent, collagen based, under product code LMF. The record does not identify a supplement type or reason, so no change to an earlier PMA can be described from these fields. The statement reports the device's intended purpose as stated in the approval; it does not independently establish safety or clinical effectiveness.
FDA approval order statement
Approval for the SURGIFOAM Absorbable Gelatin Sponge, U.S.P. This device is indicated for surgical procedures (except urologic, ophthalmic and neurologic) for hemostasis, when control of capillary, venous and arteriolar bleeding by pressure, ligature and other conventional procedures is ineffective or impractical.
- Regulatory pathway
- Original PMA
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Sep 30, 1999
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P990004
- Regulatory pathway
- Premarket approval application
- Applicant
- Ferrosan Meidcal Devices A/S
- Product code
- LMF
- Decision code
- APPR
- Decision date
- Sep 30, 1999
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Agent, absorbable hemostatic, collagen based.
- Applicant
- Ferrosan Meidcal Devices A/S
- Product code
- LMF
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P990004 received
Application receipt date recorded by FDA.
P990004 · FDA decision
APPR
P990004/S080 · Related supplement
SURGIFOAM Absorbable Gelatin Sponge
Timeline entries are records held by MedtechLedger for P990004. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P990004
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
SURGIFOAM Absorbable Gelatin SpongeP990004/S080 | Ferrosan Meidcal Devices A/S | PMA supplement | Sep 18, 2026 | FDA |
Explore the linked device profile
Other records with product code LMF
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| C.R. Bard, Inc. | PMA supplement | Sep 29, 2026 | FDA | |
| Integra LifeSciences Corporation | PMA supplement | Sep 18, 2026 | FDA | |
| Integra LifeSciences Corporation | PMA supplement | Sep 18, 2026 | FDA | |
| Integra LifeSciences Corporation | PMA approval | Nov 8, 1985 | FDA | |
COLLASTATP810006 | Integra LifeSciences Corporation | PMA approval | Dec 10, 1981 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Ferrosan Meidcal Devices A/S
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Sydmarken 5, Soeborg, 08876
Sources and methodology
- Original FDA record: P990004
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

